OakChart

ARS Pharmaceuticals Inc

SPRYHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:37 PM ET

3.88+0.31 (8.68%)
2026-11-11 21:37 CET
Market cap
358.88 USD m
Revenue, TTM
122.14 USD m
Net income, TTM
-199.87 USD m
Free cash flow, TTM
-183.07 USD m
EPS diluted, TTM
-2.01
P/E
-
Compare

Price

SPRY against its 20, 50 and 200-day averages
2050200miss
2.004.006.008.0010.004.0M8.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SPRYclose 3.8820-day 3.6350-day 4.15200-day 7.103.8852w low

70.5% under the 52-week high of 13.15 on 12 Jan 2026. 52-week low 2.44 on 6 Nov 2026. Last 15 sessions, 78.5% high to low

Volume 1.50× normal · the line is the 50-bar volume average

Profile

SPRY
52-week range, 13% of the way up
2.4413.15

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

IndexRUT
Employees163
IPODec 04, 2020
Beta0.93
ATR, 14d0.36
Rel volume1.50
Short float28.79%
Insider own34.38%
Inst own67.49%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap390.05M
Enterprise Value373.51M
Income-199.87M
Sales122.14M
Book/sh-0.12
Cash/sh1.38
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees163
IPODec 04, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S3.19
P/B-
P/C2.82
P/FCF-
EV/EBITDA-
EV/Sales3.06
Quick Ratio3.07
Current Ratio3.25
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.01
EPS next Y-0.74
EPS next Q-0.28
EPS this Y-4.02%
EPS next Y59.12%
EPS next 5Y52.26%
EPS past 3/5Y-26.04% -12.85%
Sales past 3/5Y300.09% -
EPS Y/Y TTM-148.35%
Sales Y/Y TTM-14.45%
EPS Q/Q31.04%
Sales Q/Q16.03%
EarningsNov 05 AMC
EPS/Sales Surpr.-18.03% -10.20%

Ownership

Insider Own34.38%
Insider Trans-0.08%
Inst Own67.49%
Inst Trans-4.73%
ROA-64.03%
ROE-294.57%
ROIC-181.94%
Gross Margin71.03%
Oper. Margin-161.50%
Profit Margin-163.64%
SMA206.78%
SMA50-6.53%
SMA200-45.32%
Trades-

Technical

Shs Outstand100.25M
Shs Float65.96M
Short Float28.79%
Short Ratio10.66
Short Interest18.99M
52W High13.15 -70.49%
52W Low2.44 59.02%
Volatility16.30% 9.57%
ATR (14)0.36
RSI (14)53.19
Beta0.93
Rel Volume1.50
Avg Volume1.78M
Volume2,516,585

Performance

Perf Week27.21%
Perf Month-4.20%
Perf Quarter-36.39%
Perf Half Y-51.56%
Perf YTD-66.70%
Perf Year-55.76%
Perf 3Y4.02%
Perf 5Y-53.92%
Perf 10Y-
Recom1.25
Target Price17.00
Prev Close3.57
Price3.88
Change %8.68%

Analyst ratings

latest 10 of 16
DateActionAnalystRating changeTargetImplied
Nov 06, 2026DowngradeRRaymond JamesStrong Buy → Outperform$17+338.1%
Apr 09, 2026InitiatedNNorthland CapitalOutperform$25+544.3%
Nov 04, 2025ResumedRRoth CapitalBuy$30+673.2%
Sep 04, 2025InitiatedRRoth CapitalBuy$40+930.9%
Mar 07, 2025InitiatedBScotiabankSector Outperform$30+673.2%
Feb 10, 2025InitiatedOOppenheimerOutperform$40+930.9%
Aug 20, 2024InitiatedCCantor FitzgeraldOverweight
Aug 13, 2024UpgradeRRaymond JamesOutperform → Strong Buy$18 → $22+467.0%
Aug 12, 2024ReiteratedLLeerink PartnersOutperform$19 → $20+415.5%
Jul 25, 2024InitiatedRRaymond JamesOutperform$18+363.9%

Peers

Mkt cap
TickerCompanyMkt cap
AQSTAquestive Therapeutics Inc446.82M
DBVTDBV Technologies ADR745.43M
VTRSViatris Inc24.10B
AMRXAmneal Pharmaceuticals Inc7.60B
AMPHAmphastar Pharmaceuticals Inc1.22B
PHARPharming Group NV ADR926.52M
TEVATeva- Pharmaceutical Industries Ltd50.17B
APMDApnimed Inc691.27M
REGNRegeneron Pharmaceuticals Inc98.73B
NVSNovartis AG ADR293.43B

Insider trading

latest 14 of 30
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
ERIC KARASOfficerNov 09 '26Proposed Sale2.88139,588402,362Nov 09 05:15 PM
ERIC KARASOfficerOct 30 '26Proposed Sale3.3880,000270,272Oct 30 04:30 PM
ERIC KARASOfficerOct 19 '26Proposed Sale4.10100,000410,240Oct 19 04:22 PM
ERIC KARASOfficerOct 01 '26Proposed Sale4.26100,000426,097Oct 01 04:29 PM
ERIC KARASOfficerSep 30 '26Proposed Sale4.32100,000431,560Sep 30 04:29 PM
RICHARD LOWENTHALOfficerSep 11 '26Proposed Sale5.0635,000176,995Sep 11 04:18 PM
ERIC KARASOfficerSep 11 '26Proposed Sale4.9614,06469,762Sep 11 04:10 PM
RICHARD LOWENTHALOfficerSep 04 '26Proposed Sale5.6175,000421,058Sep 04 04:09 PM
RICHARD LOWENTHALOfficerSep 03 '26Proposed Sale5.8419,805115,564Sep 03 04:31 PM
RICHARD LOWENTHALOfficerSep 02 '26Proposed Sale5.958405,000Sep 02 05:23 PM
SARINA TANIMOTOOfficerSep 01 '26Proposed Sale6.0145,388272,850Sep 01 04:52 PM
SARINA TANIMOTOOfficerAug 31 '26Proposed Sale5.8263,289368,099Aug 31 04:08 PM
SARINA TANIMOTOOfficerAug 20 '26Proposed Sale5.9225,000147,970Aug 20 05:32 PM
RICHARD LOWENTHALOfficerAug 20 '26Proposed Sale5.9325,000148,160Aug 20 04:26 PM

Held by

AUM
TickerCompanyAUM
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B
LABUDirexion Daily S&P Biotech Bull 3X ETFAUM: 583.37M

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.360-0.305-0.36037.7141.994
2026Q22026-08-13-0.630-0.478-0.62833.6631.324
2026Q12026-05-15-0.610-0.516-0.61122.6822.205
2025Q42026-03-09-0.410-0.430-0.41728.1025.626
2025Q32025-11-10-0.520-0.454-0.51832.5028.676
2025Q22025-08-13-0.460-0.458-0.45615.7213.786
2025Q12025-05-14-0.350-0.338-0.3467.977.486
2024Q42025-03-200.480-0.2380.51086.605.654
2024Q32024-11-13-0.200-0.143-0.1972.070.584
2024Q22024-08-06-0.130-0.111-0.1290.501.003
2024Q12024-05-09-0.110-0.099-0.1070.000.002
2023Q42024-03-21-0.070-0.137-0.0740.000.003
2023Q32023-11-09-0.160-0.178-0.1560.000.003
2023Q22023-08-10-0.180-0.167-0.1830.010.003
2023Q12023-05-15-0.160-0.157-0.1590.020.003
2022Q42023-03-23-0.260-0.1280.2900.650.092

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-9.582-6.708-0.9490.000.00
2021FY-2.560-2.492-0.7010.000.00
2022FY-0.870-0.941-0.8681.321.27
2023FY-0.570-0.613-0.5710.030.01
2024FY0.080-0.6580.07889.158.48
2025FY-1.740-1.718-1.74084.2881.73
2026FY--1.810--120.44
2027FY--0.740--165.44
2028FY--0.189--245.61
2029FY-0.137--307.09
2030FY-0.190--353.12

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0641329.5222.2840.20
2026Q4S2026-11-0540230.3126.6037.90
2026Q4S2026-10-2840230.3126.6037.90
2026Q4S2026-10-1240430.3126.6037.90
2026Q4S2026-09-0441330.8028.3037.90
2026Q4S2026-08-1441331.2028.3039.50
2026Q4S2026-08-0740235.9528.0143.27
2026Q4S2026-07-2940235.9428.0143.27
2026Q4S2026-07-0840335.9428.0143.27
2026Q4S2026-06-2440336.7731.3043.27
2026Q4S2026-06-2341241.2931.7056.50
2026Q4S2026-05-2751240.9831.7056.50
2026Q4S2026-05-2651240.9831.6956.50
2026Q4S2026-05-1551240.9831.7056.50

Estimate history

EPS, annual-0.532-0.725-0.949-0.701-0.868-0.5710.078-1.738-2.0124
Period20182019202020212022202320242025TTM
EPS, quarterly-0.1970.51-0.346-0.456-0.518-0.417-0.611-0.628-0.357
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0005.5061.3160.0389.14984.278122.14
Period20182019202020212022202320242025TTM
Sales, quarterly2.06886.5817.97315.71732.50128.08722.68133.65837.71
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual33.06733.06734.70130.36993.94396.41597.95499.291100.248
Period20182019202020212022202320242025MRQ
Shares, quarterly97.14797.95498.1398.69898.84499.29199.399.438100.248
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue122.1484.2889.150.031.325.510.000.000.00
Cost of Goods Sold Incl. D&A35.3820.421.190.070.320.211.711.551.42
Gross Profit86.7563.8587.96-0.041.005.29-1.71-1.55-1.42
Selling, General and Administrative Excl. Other284.00243.3091.0567.4836.5124.7531.2122.5216.90
Research and Development30.7413.1819.5820.2718.3820.2723.9421.5014.80
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-197.25-179.45-3.08-67.52-35.52-19.45-32.92-24.07-18.32
Interest Expense-2.600.000.00--0.03--
Unusual Expense--0.000.000.140.000.000.00-0.70
Net Income Before Taxes-199.95-171.388.29-54.37-34.68-20.24-32.95-23.97-17.58
Income Taxes-0.08-0.080.290.000.000.000.000.000.00
Consolidated Net Income-199.87-171.308.00-54.37-34.68-20.24-32.95-23.97-17.58
Net Income From Continuing Operations-199.87-171.308.00-54.37-34.68-20.24-32.95-23.97-17.58
Net Income-199.87-171.308.00-54.37-34.68-20.24-32.95-23.97-17.58
EPS (Recurring)-2.00-1.740.08-0.57-0.87-0.70-0.95-0.72-0.55
EPS (Basic, Before Extraordinaries)-2.01-1.740.08-0.57-0.87-0.70-0.95-0.72-0.53
EPS (Diluted)-2.01-1.740.08-0.57-0.87-0.70-0.95-0.72-0.53
EBITDA-195.60-178.08-2.88-67.45-35.20-19.24-31.21-22.52-16.90
Non-Operating Income (Expense)4.7710.6711.3713.150.97-0.790.000.100.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense29.0417.4611.489.235.842.832.640.150.29
Price To Sales Ratio3.5213.6312.1217,392.67258.9934.92---
Gross Margin71.0375.7798.67-143.3375.7696.13---
Operating Margin-161.50-212.92-3.46-225,066.67-2,698.78-353.32---
Net Margin-163.64-203.258.97-181,216.67-2,635.41-367.65---
Shares Outstanding100.2599.2997.9596.4193.9430.3734.7033.0733.07
Market Capitalization358.88358.881,025.31526.07307.58233.611,612.251,462.64-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue37.7133.6622.6828.0932.5015.727.9786.58
Cost of Goods Sold Incl. D&A10.1012.856.296.158.194.981.091.02
Gross Profit27.6120.8116.3921.9324.3110.736.8885.56
Selling, General and Administrative Excl. Other61.7882.2876.5463.4077.5058.3544.0638.36
Research and Development18.264.704.343.442.754.042.953.03
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-34.17-61.47-60.15-41.47-53.19-47.61-37.1847.20
Interest Expense2.552.482.44--0.000.000.00
Unusual Expense0.000.00---0.100.10-0.100.00
Net Income Before Taxes-35.59-62.34-60.62-41.40-51.15-44.88-33.9450.22
Income Taxes0.000.000.00-0.080.000.000.000.29
Consolidated Net Income-35.59-62.34-60.62-41.32-51.15-44.88-33.9449.93
Net Income From Continuing Operations-35.59-62.34-60.62-41.32-51.15-44.88-33.9449.93
Net Income-35.59-62.34-60.62-41.32-51.15-44.88-33.9449.93
EPS (Recurring)-0.36-0.63-0.61-0.42-0.52-0.46-0.350.51
EPS (Basic, Before Extraordinaries)-0.36-0.63-0.61-0.42-0.52-0.46-0.350.51
EPS (Diluted)-0.36-0.63-0.61-0.42-0.52-0.46-0.350.51
EBITDA-33.76-61.05-59.75-41.05-52.80-47.34-36.9047.35
Non-Operating Income (Expense)1.141.601.970.061.942.833.143.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.1212.397.421.105.695.375.303.37
Price To Earnings Ratio------164.02-
Price To Sales Ratio3.526.808.0613.696.9615.2812.7011.59
Gross Margin73.2261.8372.2978.0974.8068.2986.2898.82
Operating Margin-90.62-182.62-265.18-147.63-163.66-302.95-466.2954.51
Net Margin-94.37-185.21-267.26-147.13-157.38-285.57-425.6957.67
Shares Outstanding100.2599.4499.3099.2998.8498.7098.1397.95
Market Capitalization358.88795.42797.361,151.59993.201,713.831,234.351,025.31

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments244.99314.02228.36274.3860.06386.579.9820.16
Short Term Receivables26.359.160.801.010.000.000.000.00
Inventories8.375.210.000.000.000.000.000.00
Other Current Assets5.195.902.412.310.674.090.550.62
Total Current Assets284.90334.30231.56277.7060.73390.6610.5320.78
Net Property, Plant & Equipment2.461.070.820.770.693.804.576.02
Total Investments and Advances0.000.000.000.000.000.350.550.75
Intangible Assets14.457.370.000.000.000.000.000.00
Other Assets25.848.420.802.960.020.000.000.00
Total Assets327.65351.15233.19281.4461.45394.8015.6527.55
Short Term Debt Incl. Current Port. of LT Debt0.590.040.240.233.621.7412.303.53
Accounts Payable5.729.870.761.661.792.583.520.78
Income Tax Payable--0.000.170.00---
Other Current Liabilities32.8313.531.393.382.785.282.110.84
Total Current Liabilities39.1523.442.395.448.199.6017.935.14
Long Term Debt96.370.000.040.255.412.333.324.21
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities77.8870.920.002.853.080.000.000.00
Total Liabilities213.3994.362.438.5516.6811.9321.259.35
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.0076.040.0053.1753.17
Common Equity114.26256.80230.76272.89-31.27382.88-58.78-34.98
Total Shareholders Equity114.26256.80230.76272.8944.77382.88-5.6018.20
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity114.26256.80230.76272.8944.77382.88-5.6018.20
Total Liabilities & Stockholders Equity327.65351.15233.19281.4461.45394.8015.6527.55
Book Value Per Share1.152.622.392.90-1.0311.03-1.78-1.06
Tangible Book Value Per Share1.012.552.392.90-1.0311.03-1.78-1.06
Full-Time Employees16316026209054--
Price to Book Ratio-29.945.102.211.080.754.20-23.65-
Return on Assets-50.472.74-21.13-11.28-8.87-16.05-110.97-
Return on Equity-92.333.28-21.59-11.82-9.47-17.47-380.61-
Return on Invested Capital-81.333.11-23.56-12.70-40.34-8.55--78.47
Quick Ratio7.0614.0496.8551.017.4240.690.594.04
Current Ratio7.2814.2696.8551.017.4240.690.594.04

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-199.87-171.308.00-54.37-34.68-20.24-32.95-23.97-17.58
Depreciation1.651.370.080.070.320.211.711.551.42
Other Funds (Non Cash)33.2619.077.282.367.042.832.670.22-0.28
Funds from Operations-164.97-150.8615.36-51.94-27.32-17.20-28.57-22.20-16.44
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-18.11-20.00-1.81-7.33-12.75-0.36-2.633.30-0.43
Cash from Operating Activities-183.07-170.8713.55-59.27-40.08-17.56-31.20-18.90-16.88
Capital Expenditures0.00-0.34-0.56-0.17-0.20-0.06-0.92-0.10-0.45
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments118.8964.97-98.04-87.000.000.000.000.000.00
Purchase of Investments-116.57-242.03-356.04-272.000.000.000.000.000.00
Sale Or Maturity of Investments235.46307.00258.00185.000.000.000.000.000.00
Other Uses-2.00-7.86-7.500.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities116.8956.77-106.10-87.18-0.20-0.06-0.92-0.10-0.45
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock5.185.683.026.900.5754.98409.210.0220.25
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock5.185.683.026.900.5754.98409.210.0220.25
Proceedsfrom Stock Options0.000.000.000.000.0054.81409.030.0019.97
Issuance or Reduction of Debt, Net24.2496.260.000.00-8.68-1.82-0.708.59-0.85
Change in Long Term Debt24.2496.260.000.000.000.000.000.000.00
Issuance of Long Term Debt24.2496.260.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow2.822.6669.380.00198.840.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities32.24104.6072.406.90190.7353.16408.518.6119.40
Net Change in Cash-33.94-9.50-20.15-139.55150.4635.54376.39-10.382.08
Free Cash Flow-183.07-171.2112.98-59.44-40.28-17.62-32.11-18.99-17.32
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow--83.19------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments138.35143.84200.97244.99288.21240.13
Short Term Receivables53.2647.6429.4626.3537.6926.08
Inventories11.7111.698.828.377.788.74
Other Current Assets7.718.345.995.195.186.49
Total Current Assets211.03211.51245.24284.90338.86281.44
Net Property, Plant & Equipment1.932.082.292.462.652.64
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets13.6213.9014.1814.4514.7312.97
Other Assets24.9122.0025.8725.8416.5616.43
Total Assets251.48249.50287.57327.65372.80313.47
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.590.580.59
Accounts Payable5.425.204.715.728.3815.56
Other Current Liabilities59.4855.6644.9132.8341.9129.45
Total Current Liabilities64.9060.8649.6139.1550.8845.60
Long Term Debt121.8196.6896.5296.3797.181.07
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities76.7379.4480.1377.8877.0974.48
Total Liabilities263.44236.98226.26213.39225.15121.15
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-11.9612.5161.31114.26147.66192.32
Total Shareholders Equity-11.9612.5161.31114.26147.66192.32
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-11.9612.5161.31114.26147.66192.32
Total Liabilities & Stockholders Equity251.48249.50287.57327.65372.80313.47
Book Value Per Share-0.120.130.621.151.491.95
Tangible Book Value Per Share-0.26-0.010.471.011.341.82
Full-Time Employees---163--
Price to Book Ratio-29.9412.976.987.805.167.48
Return on Assets-64.03-76.53-64.39-50.47-27.11-17.94
Return on Equity-294.57-210.35-136.40-92.33-45.92-23.56
Return on Invested Capital-32.40-57.09-38.41-19.62-20.89-23.21
Quick Ratio3.073.284.777.066.515.98
Current Ratio3.253.484.947.286.666.17

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-35.59-62.34-60.62-41.32-51.15-44.88
Depreciation0.410.420.400.420.390.28
Other Funds (Non Cash)7.8613.836.684.884.786.06
Funds from Operations-27.31-48.09-53.54-36.02-45.98-38.54
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-6.41-12.848.60-7.46-1.07-1.05
Cash from Operating Activities-33.71-60.93-44.95-43.48-47.05-39.59
Capital Expenditures0.000.000.000.00-0.20-0.05
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments23.4141.5727.7926.11-38.9248.62
Purchase of Investments-33.06-19.91-14.71-48.89-127.42-31.38
Sale Or Maturity of Investments56.4761.4842.5075.0088.5080.00
Other Uses0.000.000.00-2.00-5.860.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities23.4141.5727.7924.11-44.9848.57
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.560.790.061.780.482.70
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.560.790.061.780.482.70
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net24.970.000.00-0.7396.990.00
Change in Long Term Debt24.970.000.00-0.7396.990.00
Issuance of Long Term Debt24.970.000.00-0.7396.990.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.232.410.100.082.580.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities27.763.200.161.13100.052.70
Net Change in Cash17.46-16.16-17.00-18.248.0211.68
Free Cash Flow-33.71-60.93-44.95-43.48-47.24-39.64

Revenue breakdown

Product2024: 7.26M 2025: 72.19M
Revenue Under Collaboration Agreements2024: 81.53M 2025: 9.72M
Revenue Under Supply Agreements2024: 365.00K 2025: 2.37M
Non-US2024: 81.89M 2025: 12.09M
United States2024: 7.26M 2025: 72.19M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3028.79%19.0M66.0M1.66M
2026-10-1530.38%19.8M65.3M1.85M
2026-09-3032.48%21.2M65.3M1.84M
2026-09-1535.36%23.1M65.3M2.05M
2026-08-3135.57%23.2M65.3M2.01M
2026-08-1435.20%23.0M65.2M2.08M
2026-07-3133.26%21.5M64.5M2.03M
2026-07-1535.15%22.7M64.5M1.83M
2026-06-3033.70%21.7M64.5M1.79M
2026-06-1535.81%23.1M64.5M1.68M
2026-05-2940.68%25.5M62.7M1.68M
2026-05-1541.35%25.9M62.7M1.53M
2026-04-3041.83%26.2M62.6M1.40M
2026-04-1542.74%26.8M62.6M1.34M
2026-03-3140.79%25.3M62.1M1.49M
2026-03-1338.18%23.7M62.1M1.41M
2026-02-2736.78%22.8M61.9M1.47M
2026-02-1335.95%22.2M61.9M1.76M
2026-01-3035.16%21.4M60.9M1.96M
2026-01-1533.23%20.2M60.9M1.98M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.601.601.603.58916025.000.928-0.0110.001
call5.000.000.050.031.6481910.000.200-0.0160.002
call7.500.001.800.052.62320.000.000.081-0.0130.001
put2.500.000.050.0117.2241.000.00-0.066-0.0740.001
put5.000.801.950.874.9421.000.00-0.866-0.0090.001
put7.503.304.500.006.9670.000.00-0.919-0.0130.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09144Filing for proposed sale of securities under Rule 144.SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-043Initial statement of beneficial ownership of securities2026-10-26SEC
2026-10-30144Filing for proposed sale of securities under Rule 144.SEC
2026-10-19144Filing for proposed sale of securities under Rule 144.SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-30144Filing for proposed sale of securities under Rule 144.SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-03144Filing for proposed sale of securities under Rule 144.SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-08-31144Filing for proposed sale of securities under Rule 144.SEC
2026-08-20144Filing for proposed sale of securities under Rule 144.SEC
2026-08-20144Filing for proposed sale of securities under Rule 144.SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-173Initial statement of beneficial ownership of securities2026-08-17SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-07-27SCHEDULE 13GSEC
2026-07-178-KCurrent report2026-07-15SEC
2026-07-14SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-0600283.55K2
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-11001.67M2

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.10.94%
Rubric Capital Management LP8.60%
ORBIMED ADVISORS LLC8.35%
DEERFIELD MANAGEMENT COMPANY, L.P.7.56%
BlackRock, Inc.5.35%
Tyro Capital Management LLC4.49%
SR ONE CAPITAL MANAGEMENT, LP4.04%
STATE STREET CORP3.76%
UBS Group AG3.69%
Capital World Investors2.77%

Funds

Fund% owned
SMALLCAP World Fund Inc2.70%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.30%
abrdn Healthcare Opportunities Fund1.82%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.76%
iShares Russell 2000 ETF1.62%
abrdn Healthcare Investors1.59%
GENERAL AMERICAN INVESTORS CO INC0.91%
VANGUARD EXTENDED MARKET INDEX FUND0.75%
Fidelity Small Cap Index Fund0.68%
abrdn Life Sciences Investors0.66%

OakChart. SPRY. Cached 15 minutes.